Navigation Links
Managed Care Pull-Through Initiatives Suffer from Poor Measurement of ROI

CHAPEL HILL, N.C., Aug. 5 /PRNewswire/ -- Increased market share is the most important success indicator for measuring effectiveness of managed care pull-through programs. However, gauging the Return on Investment for pull-through initiatives is a challenge. For 33 percent of companies, insufficient metrics and analysis is a hurdle for increasing pull-through.

Difficulty in identifying appropriate metrics to quantify the program's success results in a pull-through initiative with insufficient analysis and lack of information necessary to make mid-course corrections, according to "Managed Care Pull-Through Excellence: From Formulary Access to Increased Market Share," conducted for a partner of Best Practices, LLC.

"You have to decide at the beginning what 'good' looks like," explains an interviewed associate director. "If you reach that, you've done a great job. If not, you have to reevaluate to see what's not working and make changes."

Download a complimentary summary of "Managed Care Pull-Through Excellence: From Formulary Access to Increased Market Share" at It includes selected best practices drawn from extensive primary research with executives from 24 leading pharmaceutical companies including, Pfizer, Takeda, GlaxoSmithKline, Daiichi-Sankyo and Boehringer Ingelheim.

The full 85-page report contains more than 250 benchmark metrics and 40 best practices, providing account managers, sales leaders and brand executives a roadmap to identify and close performance gaps in their own pull-through organizations and to improve their processes, programs and activities.

Key topics of this primary research include:

  • Contracting strategies that support pull-through
  • Customer communication topics, channels and timing
  • Effective activities and programs
  • Use of program evaluation metrics
  • Key challenges faced in accomplishing Managed Care pull-through
  • Best practices in achieving pull-through effectiveness

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Using the Market Research Function to Create Success in the Critical Managed Markets Sector
2. Effective Market Research Critical to Success in Managed Markets
3. New Research from Best Practices, LLC can Improve Formulary Access and Product Placement for Biopharma Companies: Managed Markets Market Research
4. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
5. New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
6. Increasing Market Share After Product Wins Place on Managed Care Formulary
7. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results
8. HIGPA Applauds Adoption of New Group Purchasing Industry Initiatives to Further Increase Transparency and Access in the Healthcare Sector
9. West Wireless Health Institute and GE Healthcare to Collaborate on Technology and Educational Initiatives
10. Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results
11. Telehealth: Nurse Support Initiatives for Hospitals from Corathers Health
Post Your Comments:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):